“Real world outcomes of intravitreal brolucizumab for persistent diabetic macular edema”
Intravitreal brolucizumab helped improve visual acuity in patients with P-DME and achieved a reduction of 54.1% in the CRT at a longer mean reinjection interval. The rate of intraocular inflammation was 5.2% without any permanent visual impairment.
Authors
- Mudit Tyagi (ORCID: https://orcid.org/0000-0001-9211-917X)
- Saarang Hansraj (ORCID: https://orcid.org/0000-0002-9553-4560)
- Vishal Raval (ORCID: https://orcid.org/0000-0002-8446-2696)
- Raja Narayanan (ORCID: https://orcid.org/0000-0001-9688-5859)
- Ritesh Narula (ORCID: https://orcid.org/0000-0003-0192-0178)
Institutions
- L V Prasad Eye Institute (IN)
Publication Details
- Journal
- International Journal of Retina and Vitreous
- Published
- 2025-09-30
- DOI
- https://doi.org/10.1186/s40942-025-00708-y
- Citations
- 1
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.71
Funders
- Hyderabad Eye Research Foundation